Renalytix AI PLC ADR (RNLX): Price and Financial Metrics
GET POWR RATINGS... FREE!
RNLX POWR Grades
- Sentiment is the dimension where RNLX ranks best; there it ranks ahead of 80.09% of US stocks.
- RNLX's strongest trending metric is Growth; it's been moving up over the last 179 days.
- RNLX ranks lowest in Quality; there it ranks in the 0th percentile.
RNLX Stock Summary
- For RNLX, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
- RNLX's price/sales ratio is 126.5; that's higher than the P/S ratio of 97.94% of US stocks.
- With a year-over-year growth in debt of -100%, Renalytix plc's debt growth rate surpasses only 0% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Renalytix plc, a group of peers worth examining would be NURO, SCWX, NTGR, DIOD, and IBIO.
- To check out Renalytix plc's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001811115.
RNLX Valuation Summary
- RNLX's price/earnings ratio is -122.7; this is 436.16% lower than that of the median Healthcare stock.
- RNLX's price/sales ratio has moved NA NA over the prior 14 months.
- Over the past 14 months, RNLX's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for RNLX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RNLX | 2021-08-31 | 987.0 | 12.6 | -122.7 | -114.2 |
| RNLX | 2021-08-30 | 1067.6 | 13.6 | -132.8 | -124.2 |
| RNLX | 2021-08-27 | 954.9 | 12.2 | -118.7 | -110.2 |
| RNLX | 2021-08-26 | 892.0 | 11.4 | -110.9 | -102.4 |
| RNLX | 2021-08-25 | 830.8 | 10.6 | -103.3 | -94.8 |
| RNLX | 2021-08-24 | 852.0 | 10.8 | -106.0 | -97.4 |
RNLX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RNLX has a Quality Grade of F, ranking ahead of 2.15% of graded US stocks.
- RNLX's asset turnover comes in at 0.017 -- ranking 78th of 81 Healthcare stocks.
- 500 - Internal server error
The table below shows RNLX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.017 | 0.425 | -8.200 |
| 2021-03-31 | 0.014 | 0.582 | -0.987 |
| 2020-06-30 | 0.000 | NA | 4.057 |
RNLX Stock Price Chart Interactive Chart >
RNLX Price/Volume Stats
| Current price | $4.00 | 52-week high | $34.98 |
| Prev. close | $4.14 | 52-week low | $3.47 |
| Day low | $3.93 | Volume | 51,600 |
| Day high | $4.41 | Avg. volume | 110,994 |
| 50-day MA | $4.48 | Dividend yield | N/A |
| 200-day MA | $12.49 | Market Cap | 149.52M |
Renalytix AI PLC ADR (RNLX) Company Bio
Renalytix AI Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded on March 15,2018 and is headquartered in Penarth, the United Kingdom.
Latest RNLX News From Around the Web
Below are the latest news stories about Renalytix plc that investors may wish to consider to help them evaluate RNLX as an investment opportunity.
KidneyIntelX™ Clinical Results Presented at World Congress of Nephrology Demonstrate Improved Prediction of Kidney Function Over Standard of CareData highlights strength of KidneyIntelX for clinical use in early-stage diabetic kidney disease patients beyond commonly used markers UACR and historical eGFR change over timeNEW YORK and SALT LAKE CITY, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the presentation of new clinical data for KidneyIntelX™ bioprognostic™ testing at the World Congress of Nephrology Annual Meeting. The results provide robust prognostic information demonstrating the value |
Renalytix to Present at Cowen 42nd Annual Health Care ConferenceNEW YORK and SALT LAKE CITY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming virtual Cowen 42nd Annual Health Care Conference. Renalytix’s management is scheduled to participate in a fireside chat on Wednesday, March 9, 2022, at 10:30 a.m. EST. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at inv |
Renalytix to Appoint Timothy Scannell to Board of DirectorsNEW YORK and SALT LAKE CITY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced its intention to appoint Timothy Scannell to its board of directors as an independent non-executive director. Mr. Scannell is a distinguished leader in healthcare innovation, who brings more than 30 years of experience from his time at Stryker, one of the world’s leading medical technology companies. During his time as President and C.O.O., Mr. Scannell was responsible for all |
Renalytix to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceNEW YORK and SALT LAKE CITY, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Renalytix’s management is scheduled to participate in a fireside chat on Tuesday, February 15, 2022, at 3:30 p.m. EST. Due to the format of this virtual event the presentation will not be webcast. The company will be available f |
Renalytix AI PLC Sponsored ADR (RNLX) Surges 10.4%: Is This an Indication of Further Gains?Renalytix AI PLC Sponsored ADR (RNLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
RNLX Price Returns
| 1-mo | N/A |
| 3-mo | -42.20% |
| 6-mo | -74.84% |
| 1-year | -87.05% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -74.84% |
| 2021 | -0.62% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...